Interleukin (IL)-13 as a Marker in Pediatrics Asthma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

19 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-11-30

Study Completion Date

2009-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Asthma is a very common childhood chronic illness and is generally more severe in African Americans. The investigators attempted to determine whether a specific immune marker is associated with lung function and asthma severity.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study examined the relationship between Interleukin (IL)-13 from phytohemagglutinin-activated polymorphonuclear blood cells and asthma severity, lung function (measured as FEV1%), and total serum IgE levels in African American children with clinically diagnosed asthma

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

African American children with stable asthma Asthma severity Interleukin 13 from PHA stimulated PBMC Lung function (FEV1%) Total serum IgE Pediatrics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Children with asthma

African American children with clinically diagnosed stable asthma

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* African-American race, born in the U.S.
* Age 8-15 years
* Clinical diagnosis of asthma
* Subject is able to understand and follow verbal instructions in English

Exclusion Criteria

* Asthma exacerbation in the 4 weeks preceding the research visit
* Oral/IV steroid use in the 4 weeks preceding the research visit
* Upper or lower respiratory tract infection in the 4 weeks preceding the research visit
* Antibiotic use in the 4 weeks preceding the research visit
* Use of a short-acting bronchodilator during the 6 hours prior to spirometry (lung function testing)
* Use of a long-acting bronchodilator during the 12 hours prior to spirometry (lung function testing)

Minimum Eligible Age

8 Years

Maximum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Department of Immunology and Microbiology, Rush University Medical Center

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Byung H Yu, MD

Role: PRINCIPAL_INVESTIGATOR

Rush University Medical Center, Department of Immunology and Microbiology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rush University Medical Center; Clinic: University Consultants in Allergy and Immunology

Chicago, Illinois, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

L06121901

Identifier Type: -

Identifier Source: org_study_id